Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1.

BACKGROUND Adipose tissue produces "adipocytokines" of uncertain clinical significance. METHODS We analyzed the relationships among adiposity, adipocytokines, glycemia, and incident diabetes mellitus in 2356 white and black adults aged 70 to 79 years in the Health, Aging, and Body Composition Study who did not have diabetes at baseline. We measured the levels of adipocytokines adiponectin, leptin, interleukin 6, tumor necrosis factor alpha, and plasminogen activator inhibitor 1. Regional fat area was determined by means of computed tomography. New diabetes was defined as a self-reported diagnosis of diabetes or as a fasting plasma glucose level of 126 mg/dL or greater (>/=7.0 mmol/L) at the second, fourth, or sixth annual examination. RESULTS A total of 143 participants (14.1 cases per 1000 person-years) developed diabetes across 5 years. Visceral fat area (odds ratio [OR], 1.33; 95% confidence interval [CI], 1.10-1.60 per standard deviation increase) and body mass index (white individuals: OR, 1.65; 95% CI, 1.26-2.15 per standard deviation increase; black individuals: OR, 1.22; 95% CI, 0.99-1.51 per standard deviation increase) independently predicted incident diabetes. Adiponectin, leptin, and plasminogen activator inhibitor 1 attenuated the relationship between adiposity and diabetes. After controlling for body mass index, visceral fat, fasting glucose, fasting insulin, high-density lipoprotein cholesterol, triglycerides, and hypertension at baseline, plasminogen activator inhibitor 1 was the only adipocytokine independently associated with increased odds of diabetes (OR, 1.35; 95% CI, 1.01-1.81). Fasting glucose level at baseline remained a strong predictor of incident diabetes, whereas associations with body mass index and visceral fat were attenuated. CONCLUSIONS Adipocytokines and glycemia partially account for the relationship between adiposity and risk of type 2 diabetes due to adiposity. Plasminogen activator inhibitor 1 may be a useful predictor of diabetes in addition to measurements of body fat.

[1]  Tamara B Harris,et al.  Adipose tissue in muscle: a novel depot similar in size to visceral adipose tissue. , 2005, The American journal of clinical nutrition.

[2]  M. Lazar,et al.  How Obesity Causes Diabetes: Not a Tall Tale , 2005, Science.

[3]  David Couper,et al.  Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. , 2004, Diabetes.

[4]  K. Choi,et al.  Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans , 2004, Clinical endocrinology.

[5]  S. Hadjadj,et al.  Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period: the epidemiologic data on the insulin resistance syndrome prospective study. , 2004, Diabetes.

[6]  John A Wagner,et al.  Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin Sensitivity* , 2004, Journal of Biological Chemistry.

[7]  Nader Rifai,et al.  Inflammatory markers and risk of developing type 2 diabetes in women. , 2004, Diabetes.

[8]  J. Jansson,et al.  High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA Study , 2003, Cardiovascular diabetology.

[9]  Christopher J. Lyon,et al.  Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. , 2003, The American journal of medicine.

[10]  S. Haffner,et al.  Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians. , 2003, Diabetes care.

[11]  M. Igarashi,et al.  Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. , 2003, Diabetes care.

[12]  T. Funahashi,et al.  Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. , 2003, Diabetes care.

[13]  J. Engel,et al.  Structure-Function Studies of the Adipocyte-secreted Hormone Acrp30/Adiponectin , 2003, The Journal of Biological Chemistry.

[14]  Joachim Spranger,et al.  Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. , 2003, Diabetes.

[15]  S. Kritchevsky,et al.  Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. , 2003, Diabetes care.

[16]  T. Buchanan,et al.  Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. , 2002, Diabetes.

[17]  D. Grobbee,et al.  Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. , 2002, Diabetes care.

[18]  Jonathan Krakoff,et al.  Adiponectin and development of type 2 diabetes in the Pima Indian population , 2002, The Lancet.

[19]  D. Matthews,et al.  The assessment of insulin resistance in man , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[20]  S. Haffner,et al.  Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. , 2002, Diabetes.

[21]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[22]  L. Kuller,et al.  Prevalence and clinical implications of American Diabetes Association-defined diabetes and other categories of glucose dysregulation in older adults: the health, aging and body composition study. , 2001, Journal of clinical epidemiology.

[23]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[24]  A. Hamsten,et al.  Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin: insights into the signaling pathway. , 2001, Diabetes.

[25]  A. Newman,et al.  Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study. , 2001, Journal of applied physiology.

[26]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[27]  T. Funahashi,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance , 2022 .

[28]  D. Schneider,et al.  Identification and Localization of a Fatty Acid Response Region in the Human Plasminogen Activator Inhibitor-1 Gene , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[29]  B. Wajchenberg.  Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. , 2000, Endocrine reviews.

[30]  S. O’Rahilly,et al.  The perils of portliness: causes and consequences of visceral adiposity. , 2000, Diabetes.

[31]  J. Bastard,et al.  Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance , 2000, Diabetes/metabolism research and reviews.

[32]  D. Singer,et al.  Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. , 2000, JAMA.

[33]  P. Morange,et al.  PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[34]  S. Haffner,et al.  Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[35]  E. Boyko,et al.  Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. , 1999, Diabetes care.

[36]  Bruce M Psaty,et al.  Diabetes in older adults: comparison of 1997 American Diabetes Association classification of diabetes mellitus with 1985 WHO classification , 1998, The Lancet.

[37]  H. Lithell,et al.  Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data , 1998 .

[38]  W A Hsueh,et al.  Cardiovascular risk continuum: implications of insulin resistance and diabetes. , 1998, The American journal of medicine.

[39]  L. Fink,et al.  Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. , 1998, Journal of diabetes and its complications.

[40]  B. Goodpaster,et al.  Subcutaneous Abdominal Fat and Thigh Muscle Composition Predict Insulin Sensitivity Independently of Visceral Fat , 1997, Diabetes.

[41]  K. Polonsky,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndr , 2022 .

[42]  P. Morange,et al.  Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease , 1997, Diabetes.

[43]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.

[44]  S. Haffner,et al.  Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans--a 7-year prospective study. , 1997, Obesity research.

[45]  D. Loskutoff,et al.  Tissue Distribution and Regulation of Plasminogen Activator Inhibitor-1 in Obese Mice , 1996, Molecular medicine.

[46]  A. Kissebah.  Intra-abdominal fat: is it a major factor in developing diabetes and coronary artery disease? , 1996, Diabetes research and clinical practice.

[47]  E. Bruckert,et al.  Are free fatty acids related to plasma plasminogen activator inhibitor 1 in android obesity? , 1995, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[48]  S. Grundy,et al.  Relationships of generalized and regional adiposity to insulin sensitivity in men. , 1995, The Journal of clinical investigation.

[49]  D. Herold,et al.  Effects of Vitamin E on Susceptibility of Low-Density Lipoprotein and Low-Density Lipoprotein Subfractions to Oxidation and on Protein Glycation in NIDDM , 1995, Diabetes Care.

[50]  M. Alessi,et al.  Plasminogen Activator Inhibitor 1 and Atherothrombosis , 1993, Thrombosis and Haemostasis.

[51]  A Tremblay,et al.  Visceral Obesity in Men: Associations With Glucose Tolerance, Plasma Insulin, and Lipoprotein Levels , 1992, Diabetes.

[52]  N. Golden,et al.  in Women with , 1992 .

[53]  P. Vague,et al.  Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. , 1989, Metabolism: clinical and experimental.

[54]  P. Vague,et al.  Increased Plasminogen Activator Inhibitor Activity in Non Insulin Dependent Diabetic Patients – Relationship with Plasma Insulin , 1989, Thrombosis and Haemostasis.

[55]  M. Alessi,et al.  Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. , 1988, Blood.

[56]  M. Blombäck,et al.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.

[57]  J. Ware,et al.  On the use of repeated measurements in regression analysis with dichotomous responses. , 1979, Biometrics.